Gabelli & CO Investment Advisers, Inc. 89bio, Inc. Transaction History
Gabelli & CO Investment Advisers, Inc.
- $510 Million
- Q3 2025
A detailed history of Gabelli & CO Investment Advisers, Inc. transactions in 89bio, Inc. stock. As of the latest transaction made, Gabelli & CO Investment Advisers, Inc. holds 417,850 shares of ETNB stock, worth $6.2 Million. This represents 1.2% of its overall portfolio holdings.
Number of Shares
417,850Holding current value
$6.2 Million% of portfolio
1.2%Shares
1 transactions
Others Institutions Holding ETNB
# of Institutions
223Shares Held
157MCall Options Held
729KPut Options Held
5.84M-
Ra Capital Management, L.P. Boston, MA19.9MShares$295 Million5.01% of portfolio
-
Pentwater Capital Management LP Naples, FL11.8MShares$174 Million1.08% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.36MShares$139 Million4.33% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.1MShares$135 Million0.22% of portfolio
-
Suvretta Capital Management, LLC New York, NY8.28MShares$123 Million3.65% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $690M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...